HIV pre-exposure prophylaxis and sexually transmitted infections: intersection and opportunity.

Jenell Stewart, Jared M Baeten
Author Information
  1. Jenell Stewart: Department of Medicine, University of Washington, Seattle, WA, USA. jenells@uw.edu. ORCID
  2. Jared M Baeten: Department of Medicine, University of Washington, Seattle, WA, USA. ORCID

Abstract

Pre-exposure prophylaxis (PrEP) has revolutionized HIV prevention, but PrEP does not protect against other sexually transmitted infections (STIs). Rates of STIs are rising worldwide, with notably high incidences among PrEP-using men who have sex with men in high-income countries; in low-income and middle-income countries, data are sparse, but results from a limited number of studies among African women initiating and taking PrEP have shown high STI prevalence and incidence. Efforts aimed at markedly reducing HIV in populations worldwide include a major focus on increasing PrEP use, along with improving HIV testing and treatment in order to eliminate HIV transmission. Together, these efforts could augment continued expansion of the global STI epidemic, but they could alternatively create an opportunity to improve STI control, including the development of comprehensive sexual health programmes and research to develop new STI prevention strategies. The introduction of PrEP globally has been characterized by challenges and many successes, and its role as part of a range of robust strategies to reduce HIV infections is clear. Looking ahead, understanding rising rates of curable STIs and their relationship to HIV prevention, and considering the future directions for synergies in PrEP and STI prevention will be integral to improving sexual health.

References

  1. N Engl J Med. 2011 Aug 11;365(6):493-505 [PMID: 21767103]
  2. Int J STD AIDS. 2017 Aug;28(9):849-857 [PMID: 28632468]
  3. AIDS. 2016 Jul 31;30(12):1973-83 [PMID: 27149090]
  4. J Infect Dis. 2020 Oct 1;222(9):1432-1434 [PMID: 31495889]
  5. Curr Pediatr Rep. 2018 Jun;6(2):114-122 [PMID: 30345163]
  6. HIV Med. 2020 Nov;21(10):617-624 [PMID: 32885559]
  7. Fam Plann Perspect. 1998 Mar-Apr;30(2):67-72, 88 [PMID: 9561871]
  8. Lancet HIV. 2019 Feb;6(2):e81-e92 [PMID: 30584047]
  9. PLoS Clin Trials. 2007 May 25;2(5):e27 [PMID: 17525796]
  10. J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):587-96 [PMID: 24326606]
  11. JAMA Pediatr. 2017 Nov 1;171(11):1063-1071 [PMID: 28873128]
  12. Sex Transm Dis. 2019 Apr;46(4):271-277 [PMID: 30870326]
  13. J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):131-140 [PMID: 31180995]
  14. J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):340-8 [PMID: 24784763]
  15. J Virus Erad. 2018 Jul 1;4(3):143-159 [PMID: 30050676]
  16. JAMA. 2018 Jul 24;320(4):379-396 [PMID: 30043070]
  17. N Engl J Med. 2005 Feb 17;352(7):676-85 [PMID: 15716561]
  18. J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):74-8 [PMID: 17971715]
  19. AIDS. 2019 Jul 15;33(9):1455-1465 [PMID: 30932951]
  20. N Engl J Med. 2010 Dec 30;363(27):2587-99 [PMID: 21091279]
  21. Emerg Infect Dis. 2018 Mar;24(3):413-416 [PMID: 29460740]
  22. Sex Transm Infect. 1998 Oct;74(5):331-3 [PMID: 10195027]
  23. PLoS One. 2016 Oct 5;11(10):e0163365 [PMID: 27706174]
  24. AIDS. 2020 Apr 1;34(5):651-658 [PMID: 32167988]
  25. Lancet. 2019 Jun 15;393(10189):2428-2438 [PMID: 31056293]
  26. J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S240-7 [PMID: 23764642]
  27. Am J Obstet Gynecol. 2009 Aug;201(2):146.e1-6 [PMID: 19646565]
  28. Clin Infect Dis. 2019 Jan 18;68(3):501-504 [PMID: 29982304]
  29. Ann Epidemiol. 2015 Jun;25(6):445-54 [PMID: 25911980]
  30. Cult Health Sex. 2017 Dec;19(12):1301-1313 [PMID: 28415911]
  31. PLoS Med. 2013;10(9):e1001511 [PMID: 24058300]
  32. Clin Infect Dis. 2015 Aug 15;61(4):572-80 [PMID: 25908682]
  33. Lancet Infect Dis. 2019 Jun;19(6):658-669 [PMID: 31031172]
  34. MMWR Morb Mortal Wkly Rep. 2019 Jul 12;68(27):597-603 [PMID: 31298662]
  35. Lancet HIV. 2017 Sep;4(9):e402-e410 [PMID: 28747274]
  36. Clin Infect Dis. 2018 Aug 16;67(5):676-686 [PMID: 29509889]
  37. J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):467-473 [PMID: 30148731]
  38. AIDS Behav. 2016 Jul;20(7):1461-9 [PMID: 25835463]
  39. J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):175-183 [PMID: 28498144]
  40. Lancet HIV. 2018 Nov;5(11):e629-e637 [PMID: 30343026]
  41. Lancet. 2017 Sep 30;390(10102):1603-1610 [PMID: 28705462]
  42. PLoS One. 2015 Mar 20;10(3):e0120957 [PMID: 25793283]
  43. Ann Epidemiol. 2018 Dec;28(12):841-849 [PMID: 29983236]
  44. J Int AIDS Soc. 2019 Jul;22 Suppl 4:e25298 [PMID: 31328444]
  45. Clin Infect Dis. 2015 Mar 1;60(5):804-10 [PMID: 25409469]
  46. AIDS. 2014 Aug 24;28(13):1977-82 [PMID: 25259704]
  47. J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):21-29 [PMID: 27632233]
  48. Lancet HIV. 2018 Aug;5(8):e448-e456 [PMID: 29885813]
  49. Clin Infect Dis. 2018 Aug 31;67(6):962-964 [PMID: 29961859]
  50. J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):200-6 [PMID: 26761520]
  51. AIDS Behav. 2019 Feb;23(2):548-555 [PMID: 30117076]
  52. Sci Transl Med. 2012 Sep 12;4(151):151ra125 [PMID: 22972843]
  53. JAMA. 2016 Jul 12;316(2):191-210 [PMID: 27404187]
  54. J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):e104-e106 [PMID: 29076941]
  55. SAGE Open Med. 2018 Dec 04;6:2050312118816919 [PMID: 30574301]
  56. AIDS Patient Care STDS. 2013 Apr;27(4):248-54 [PMID: 23565928]
  57. J Virus Erad. 2018 Oct 01;4(4):215-224 [PMID: 30515300]
  58. J Infect Dis. 2016 Oct 1;214(7):1050-7 [PMID: 27029778]
  59. JAMA Netw Open. 2019 Dec 2;2(12):e1917134 [PMID: 31825501]
  60. J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):79-86 [PMID: 23466649]
  61. BMJ Glob Health. 2019 Apr 22;4(2):e001349 [PMID: 31139454]
  62. Curr Opin Infect Dis. 2020 Feb;33(1):51-58 [PMID: 31789694]
  63. AIDS Res Hum Retroviruses. 2018 Apr;34(4):337-342 [PMID: 29368537]
  64. AIDS Behav. 2018 Nov;22(11):3718-3725 [PMID: 30006791]
  65. Curr Opin HIV AIDS. 2016 Jan;11(1):3-9 [PMID: 26569183]
  66. Int J STD AIDS. 2014 Oct;25(12):851-9 [PMID: 24516075]
  67. BMJ Open. 2019 Feb 19;9(2):e026888 [PMID: 30782948]
  68. J Acquir Immune Defic Syndr. 2021 Jun 1;87(2):769-775 [PMID: 33538527]
  69. J Acquir Immune Defic Syndr. 2019 Jan 1;80(1):36-39 [PMID: 30531295]
  70. J Int AIDS Soc. 2019 Aug;22 Suppl 6:e25351 [PMID: 31468693]
  71. PLoS One. 2017 May 25;12(5):e0177770 [PMID: 28542239]
  72. MMWR Morb Mortal Wkly Rep. 2018 Oct 19;67(41):1147-1150 [PMID: 30335734]
  73. AIDS. 2018 Feb 20;32(4):523-530 [PMID: 29239887]
  74. J Infect Dis. 2014 Feb 1;209(3):325-33 [PMID: 24136792]
  75. JAMA. 2019 Jun 11;321(22):2203-2213 [PMID: 31184747]
  76. Ann Intern Med. 2014 Jul 1;161(1):11-9 [PMID: 24979446]
  77. Lancet. 2007 Apr 7;369(9568):1220-31 [PMID: 17416266]
  78. J Assoc Nurses AIDS Care. 2018 Sep - Oct;29(5):770-774 [PMID: 30146018]
  79. BMJ Open. 2020 Nov 24;10(11):e037608 [PMID: 33234617]
  80. JAMA Netw Open. 2020 May 1;3(5):e204819 [PMID: 32407506]
  81. Sex Transm Dis. 2018 Jul;45(7):452-458 [PMID: 29465664]
  82. AIDS. 2017 Jul 31;31(12):1709-1714 [PMID: 28700394]
  83. J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):52-8 [PMID: 24872136]
  84. J Fam Pract. 2019 Jun;68(5):254-261 [PMID: 31287442]
  85. Sex Transm Dis. 2016 Jan;43(1):2-8 [PMID: 26656441]
  86. Sex Transm Dis. 2018 Nov;45(11):723-727 [PMID: 29771869]
  87. Lancet Infect Dis. 2014 Nov;14(11):1055-1064 [PMID: 25300863]
  88. N Engl J Med. 2015 Dec 3;373(23):2237-46 [PMID: 26624850]
  89. AIDS. 2019 Sep 1;33(11):1773-1780 [PMID: 31149948]
  90. JAMA. 2016 Jul 12;316(2):171-81 [PMID: 27404185]
  91. Euro Surveill. 2017 Jun 22;22(25): [PMID: 28662762]
  92. Contraception. 2013 Mar;87(3):319-30 [PMID: 22995540]
  93. N Engl J Med. 2012 Aug 2;367(5):399-410 [PMID: 22784037]
  94. PLoS One. 2015 Dec 08;10(12):e0143304 [PMID: 26646541]
  95. Health Serv Res. 2015 Jun;50(3):809-29 [PMID: 25367046]
  96. Lancet HIV. 2018 Jul;5(7):e347-e356 [PMID: 29925490]
  97. JAMA Intern Med. 2016 Jan;176(1):75-84 [PMID: 26571482]
  98. Sex Transm Infect. 2020 Sep;96(6):432-435 [PMID: 31624177]
  99. Vaccine. 2020 Jun 9;38(28):4362-4373 [PMID: 32359875]
  100. Sex Transm Infect. 1999 Feb;75(1):3-17 [PMID: 10448335]
  101. Am Fam Physician. 2010 Apr 1;81(7):873-8 [PMID: 20353145]
  102. Sex Transm Infect. 2006 Jun;82 Suppl 3:iii18-25 [PMID: 16735288]
  103. AIDS Behav. 2017 Jul;21(7):2173-2179 [PMID: 27699594]
  104. Curr Opin HIV AIDS. 2016 Jan;11(1):74-9 [PMID: 26599164]
  105. Lancet. 2011 Jul 16;378(9787):279-81 [PMID: 21763939]
  106. J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):395-405 [PMID: 30973543]
  107. AIDS. 2018 Jul 17;32(11):1527-1532 [PMID: 29762169]
  108. Clin Infect Dis. 2016 Sep 1;63(5):672-7 [PMID: 27282710]
  109. Lancet Infect Dis. 2018 Mar;18(3):308-317 [PMID: 29229440]
  110. Ann Epidemiol. 2017 Apr;27(4):238-243 [PMID: 28325538]
  111. JAMA. 2019 Apr 9;321(14):1380-1390 [PMID: 30964528]
  112. Sex Transm Dis. 2016 Apr;43(4):249-54 [PMID: 26967302]
  113. Curr HIV/AIDS Rep. 2019 Jun;16(3):244-256 [PMID: 31183609]

Grants

  1. K23 MH124466/NIMH NIH HHS
  2. P30 AI027757/NIAID NIH HHS
  3. R01 AI145971/NIAID NIH HHS
  4. T32 AI007044/NIAID NIH HHS

MeSH Term

HIV Infections
Humans
Pre-Exposure Prophylaxis
Sexually Transmitted Diseases

Word Cloud

Created with Highcharts 10.0.0HIVPrEPSTIpreventionSTIsprophylaxissexuallytransmittedinfectionsrisingworldwidehighamongmencountriesimprovingopportunitysexualhealthstrategiesPre-exposurerevolutionizedprotectRatesnotablyincidencesPrEP-usingsexhigh-incomelow-incomemiddle-incomedatasparseresultslimitednumberstudiesAfricanwomeninitiatingtakingshownprevalenceincidenceEffortsaimedmarkedlyreducingpopulationsincludemajorfocusincreasingusealongtestingtreatmentordereliminatetransmissionTogethereffortsaugmentcontinuedexpansionglobalepidemicalternativelycreateimprovecontrolincludingdevelopmentcomprehensiveprogrammesresearchdevelopnewintroductiongloballycharacterizedchallengesmanysuccessesrolepartrangerobustreduceclearLookingaheadunderstandingratescurablerelationshipconsideringfuturedirectionssynergieswillintegralpre-exposureinfections:intersection

Similar Articles

Cited By